Niagen Bioscience (NASDAQ:NAGE) Stock Price Target Cut by Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE) had its price target lowered by stock analysts at Canaccord Genuity Group from $9.00 to $7.00 in a report released on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group‘s price objective would indicate a potential upside of 234.13% from the company’s current price.

NAGE has been the subject of a number of other research reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a research report on Thursday, October 15th. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $9.33.

Niagen Bioscience Price Performance

Shares of NAGE traded down $0.01 during trading hours on Friday, hitting $2.10. 347,593 shares of the company were exchanged, compared to its average volume of 838,099. The company has a market capitalization of $166.85 million, a PE ratio of 17.54 and a beta of 2.12. The firm has a fifty day simple moving average of $2.79 and a 200-day simple moving average of $3.85. Niagen Bioscience has a one year low of $2.04 and a one year high of $7.28.

Niagen Bioscience (NASDAQ:NAGE) last announced its earnings results on Wednesday, November 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). The company had revenue of $27.19 million for the quarter. Niagen Bioscience had a return on equity of 10.26% and a net margin of 8.37%. Sell-side analysts expect that Niagen Bioscience will post 0.08 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. SteelPeak Wealth LLC lifted its holdings in Niagen Bioscience by 2.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company’s stock worth $10,446,000 after purchasing an additional 77,306 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Niagen Bioscience by 47.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,378,437 shares of the company’s stock valued at $10,489,000 after purchasing an additional 761,685 shares during the last quarter. Tieton Capital Management LLC acquired a new position in Niagen Bioscience during the second quarter valued at approximately $6,407,000. Renaissance Technologies LLC raised its position in shares of Niagen Bioscience by 45.4% in the first quarter. Renaissance Technologies LLC now owns 1,328,843 shares of the company’s stock valued at $5,860,000 after purchasing an additional 414,725 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in shares of Niagen Bioscience by 16.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,071,133 shares of the company’s stock valued at $4,723,000 after purchasing an additional 150,763 shares during the period. 15.41% of the stock is owned by institutional investors.

Key Niagen Bioscience News

Here are the key news stories impacting Niagen Bioscience this week:

• Positive Sentiment: Niagen outlined a three-year, 5,000-participant Mass General Brigham trial and is targeting early 2027 commercialization of NR malate, which could expand its product pipeline. Article: Niagen outlines trial and commercialization plans
• Positive Sentiment: Third-quarter direct-to-consumer sales on the company’s website rose 13% year over year; Tru Niagen generated $23.3 million of the $27.2 million in total sales, with a 62% gross margin. Article: Third-quarter 2026 financial results
• Neutral Sentiment: The Q3 earnings call was characterized as cash-flow positive, a potentially supportive indicator, though the headline does not provide figures to assess the strength or sustainability of cash generation. Article: Q3 earnings call highlights
• Negative Sentiment: HC Wainwright cut its Q3 and Q4 2026 EPS estimates from a profit of $0.02 to a loss of $0.02 per share for each quarter. It also lowered its FY2026 and FY2027 forecasts from $0.14 to $0.05 per share, signaling weaker expected earnings.
• Negative Sentiment: Niagen reported a Q3 loss of $0.01 per share, matching consensus but down from earnings of $0.05 a year earlier. Revenue was $27.2 million and reportedly fell short of estimates, adding to concerns about growth. Article: Niagen reports Q3 loss and misses revenue estimates

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.